Clinical Trial

Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 7, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-12; most recent amendment 2025-05-03.
Status change: Not Yet Recruiting → Recruiting 2025-05-03
Trial Details
NCT Number NCT06462417
Lead Sponsor Zheng Liu
Collaborators: National Natural Science Foundation of China
Conditions Allergic Rhinitis
Enrollment 15 participants
Start Date 2024-07-11
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-07